The information on this page was delivered via a feed from the London Stock Exchange's Regulatory News Service.
RNS Number:8680I
PuriCore Plc
13 September 2006
PuriCore Announces the Appointment of Three New
Independent Non-Executive Directors
MALVERN, PENNSYLVANIA, and STAFFORD, UK, 13 September 2006 -- PuriCore plc
('PuriCore') (London Stock Exchange: PURI), the developer of a novel, safe
technology that mimics the human body's natural anti-microbial, hypochlorous
acid, today announces the appointment of three new independent non-executive
directors.
Timothy Anderson
Mr. Anderson, 60, held various executive management positions at Baxter
International (NYSE: BAX), a leading US medical technology company, from 1972 to
2002, including Senior Vice President of Strategy and Business Development from
1999 until 2002, President, Biotech Group from 1992 until 1997, Group Vice
President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999.
He continues to be a member of Baxter's Scientific Advisory Board. Mr.
Anderson is also currently a Director of Cerus Corporation (NASDAQ: CERS), Tecan
AG (Swiss: TECN), and Lake Forest Hospital. Mr Anderson will also be a member
of the PuriCore Audit Committee.
Alan Suggett, BSc, PhD, C Chem, FRSC
Dr. Suggett, 63, has over 20 years experience operating at the technical/
business interface in the medical devices field and he brings great experience
of strategic and governance leadership, most recently related to orthopedics,
minimally-invasive surgery, and wound management. Until retiring from his
full-time operational roles at the beginning of 2004, he was Group Director of
Technology at Smith & Nephew plc and a long-standing member of the Company's
Executive Committee. Previously he was Group R&D Director at Smith & Nephew and
held senior positions with Scottish & Newcastle Breweries and Unilever Research.
Dr. Suggett is also a Non-Executive Director of Intercytex Group plc (AIM:
ICX), Chairman of the Scientific Advisory Board of Photopharmica Limited,
Chairman of the Healthcare Technologies Knowledge Transfer Network, a Fellow of
the Royal Society of Chemistry, an Honorary Fellow of the Royal College of
Physicians, and a Visiting Professor at the University of York.
Jim Walsh, PhD
Dr. Jim Walsh, 48, has 20 years general management experience in the healthcare
industry with particular experience in diagnostics. He is an Executive Director
and Chief Operating Officer with Trinity Biotech Plc (NASDAQ: TRIB), an Irish
headquartered diagnostics company. Dr. Walsh also holds Non-Executive Director
positions with a number of early stage companies in the areas of micro-fluidics
and molecular biology. Previously Dr. Walsh was Managing Director of Cambridge
Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc
(AMEX: IMA). Before joining CDL, he worked with Fleming GmbH as R&D Manager.
Born in Ireland, Dr. Walsh is a graduate of the National University of Ireland
and holds a Doctorate in Inorganic Chemistry and Post Doctorate qualifications
in Immunochemistry. He will also serve on the PuriCore Remuneration Committee.
Each of the new independent Non-Executive Directors will receive options to
purchase 100,000 shares of PuriCore ordinary shares. Each share option will
have a five year life and vest one-third per year beginning on the first
anniversary of grant. The exercise price shall be five per cent over the market
price of the Company's ordinary shares on the date of grant.
Commenting on the appointments, Chris Wightman, Chairman of PuriCore, said, '
These new members of our Board bring valuable expertise and contacts to us in
the life science and medical technology industries. They add valuable
commercial experience and their participation will serve to strengthen further
the Board's corporate governance. I look forward to working with them in
shaping the future of PuriCore.'
There are no other details which are required to be disclosed under paragraph
9.6.13 R of the Listing Rules of the FSA relative to the respective appointments
of Messrs Anderson, Suggett and Walsh as Non-Executive Directors of the Company.
FOR FURTHER INFORMATION:
PuriCore plc Tel: +1 (484) 321-2701
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer
Financial Dynamics Tel: +44 (0) 20 7831 3113
David Yates
Sarah MacLeod
John Gilbert
ABOUT PURICORE PLC
PuriCore is a life sciences company focused on the development and
commercialization of its proprietary technology that mimics the production by
the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous
acid is highly effective at killing pathogens such as bacteria, viruses and
fungi and yet is safe and environmentally friendly. PuriCore's solutions have
applications in a wide range of markets where it is important to control
microbial contamination. These markets include medical device disinfection,
food safety, dental equipment decontamination, environmental remediation,
hospitality, water safety, wound management and other applications intended to
limit the spread of infectious disease, including major global disease threats
such as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis
A, H.pylori and Legionella.
PuriCore markets a portfolio of branded systems which produce hypochlorous acid
solutions on-site at a customer's location from water, electricity and common
salt. These solutions are generated at a range of concentrations and at a
nearly neutral pH range similar to the human body. They are effective as soaks,
sprays, mists and in other forms.
PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,
UK.
To receive additional information on the Company, please visit our Web site at
www.puricore.com, which does not form part of this press release.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAIFFFLARIFLIR